Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.46 |
| ▸ | CCR3 | P51677 | 3/20 | 0.46 |
| ▸ | ITGAV | P06756 | 17/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 12/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 9/20 | 0.45 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22008993 | 1.00 | KCNH2 (0.46) | KCNH2HRH1CCR3ITGAVITGB3 | |
| SCHEMBL20481396 | 1.00 | KCNH2 (0.46) | KCNH2HRH1CCR3ITGAVITGB3 | |
| SCHEMBL23788752 | 0.85 | ITGAV (0.42) | KCNH2HRH1CCR3ITGAVITGB3 | |
| SCHEMBL21832084 | 0.85 | ITGAV (0.45) | KCNH2ITGAVITGB3ITGB5ITGB1 | |
| SCHEMBL22008994 | 0.85 | ITGAV (0.44) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL22008996 | 0.85 | ITGAV (0.44) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL20481005 | 0.83 | ITGAV (0.44) | KCNH2ITGAVITGB3ITGB5ITGB1 | |
| SCHEMBL20481216 | 0.82 | ITGAV (0.53) | KCNH2ITGAVITGB3ITGB5ITGB1 | |
| SCHEMBL20481022 | 0.82 | ITGAV (0.45) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL22008992 | 0.82 | ITGAV (0.53) | KCNH2ITGAVITGB3ITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | KCNH2 1934/4885HRH1 3096/4885CCR3 1530/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | KCNH2 1951/4885HRH1 3113/4885CCR3 1805/4885 |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | KCNH2 1934/4885HRH1 3096/4885CCR3 1530/4885 |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | ITGB6, ITGA6, ITGAV | KCNH2 1934/4885HRH1 3096/4885CCR3 1530/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | KCNH2 1951/4885HRH1 3113/4885CCR3 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.